Regeneron Pharmaceuticals, Inc.

REGN

$502.34

-9.9% (1 year change)

Avg closing price

Price range

Market Cap

$52.2 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$441.00 - $664.64

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

14.86x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $52.2 Billion
Enterprise Value $51.3 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return -9.9%
52-Week High $664.64
52-Week Low $441.00
Beta 0.68
Outstanding Shares 105 Million
Avg 30 Day Volume 827 Thousand

Valuation

P/E Ratio 14.86
PEG 32.94
Earnings per Share $30.52
Price to Sales Ratio 6.36
Price to Book Ratio 4.78
Revenue to Enterprise Value 6.13
EBIT to Enterprise Value 17.58
Total Debt to Enterprise Value 0.05
Debt to Equity 0.24

Profitability

Revenue $8.37 Billion
Gross Profit $7.9 Billion
EBIT $2.92 Billion
Net Income $3.46 Billion
Profit Margin 41.36%
Quarterly Earnings Growth (YoY) +45.1%
Return on Equity 31.41%
Return on Assets 20.18%
Return on Invested Capital 20.18%

News

Looking Into Regeneron Pharmaceuticals's Return On Capital Employed

Looking Into Regeneron Pharmaceuticals's Return On Capital Employed

Looking Into Regeneron Pharmaceuticals's Return On Capital Employed Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. …

Benzinga Benzinga, 5 days ago
India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail

India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail

Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for treatment of COVID-19. Cipla will part...

Benzinga Benzinga, 6 days ago
Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study

Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study

Novartis AG (NYSE: NVS ) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to on...

Benzinga Benzinga, 8 days ago